{"id":"NCT00510952","sponsor":"Eli Lilly and Company","briefTitle":"Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)","officialTitle":"The PERSISTENT Trial: A Prospective Randomized Trial Comparing Insulin Lispro Protamine Suspension to Insulin Glargine in Patients With Type 2 Diabetes on Anti-hyperglycemic Medications","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2007-08-03","resultsPosted":"2009-11-03","lastUpdate":"2010-10-21"},"enrollment":471,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Insulin Lispro Protamine Suspension","otherNames":["Insulin Lispro Protamine Suspension (ILPS)","Neutral Protamine Lispro (NPL)","Humalog"]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"Lispro","type":"EXPERIMENTAL"},{"label":"Glargine","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.","primaryOutcome":{"measure":"Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c)","timeFrame":"Baseline, 24 Weeks","effectByArm":[{"arm":"Lispro","deltaMin":8.7,"sd":0.06},{"arm":"Glargine","deltaMin":8.69,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"0.551"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":17,"countries":["United States","Brazil","Canada","Puerto Rico"]},"refs":{"pmids":["20920045","23101951"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":229},"commonTop":["Nasopharyngitis","Headache","Influenza","Diarrhoea","Back pain"]}}